

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/00, 15/12, C07K 14/00, 14/435, 7/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/53045</b> <b>(43) International Publication Date:</b> 21 October 1999 (21.10.99)
<b>(21) International Application Number:</b> PCT/US99/07885 <b>(22) International Filing Date:</b> 9 April 1999 (09.04.99)  <b>(30) Priority Data:</b> 60/081,181 9 April 1998 (09.04.98) US Not furnished 8 April 1999 (08.04.99) US  <b>(71) Applicant:</b> GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).  <b>(72) Inventors:</b> JACOBS, Kenneth; 151 Beaumont Street, Newton, MA 02160 (US). McCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LaVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). COLLINS-RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). TREACY, Maurice; 12 Foxrock Court, Dublin 18 (IE). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US). STEININGER, Robert, J., II; 100 Reed Street, Cambridge, MA 02140 (US).  <b>(74) Agent:</b> MANDRAGOURAS, Amy, E.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM  <b>(57) Abstract</b>  Novel polynucleotides and the proteins encoded thereby are disclosed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

## SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

10 This application is a continuation-in-part of provisional application Ser. No. 60/081,181, filed April 9, 1998, which is incorporated by reference herein.

15

FIELD OF THE INVENTION

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

20

BACKGROUND OF THE INVENTION

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

35

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5       (a)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- (b)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 373 to nucleotide 960;
- (c)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 457 to nucleotide 960;
- 10       (d)     a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone PL433\_3 deposited under accession number ATCC 98730;
- (e)     a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone PL433\_3 deposited under accession number ATCC 98730;
- 15       (f)     a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone PL433\_3 deposited under accession number ATCC 98730;
- (g)     a polynucleotide encoding a mature protein encoded by the cDNA insert of clone PL433\_3 deposited under accession number ATCC 98730;
- 20       (h)     a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (i)     a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;
- 25       (j)     a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k)     a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l)     a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- 30       (m)     a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:1.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 373 to nucleotide 960; the nucleotide sequence of SEQ ID NO:1 from nucleotide 457 to nucleotide 960; the nucleotide sequence of the full-length protein coding sequence of clone PL433\_3 deposited under accession number ATCC 98730; or the  
5 nucleotide sequence of a mature protein coding sequence of clone PL433\_3 deposited under accession number ATCC 98730. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone PL433\_3 deposited under accession number ATCC 98730. In further preferred  
10 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 93  
15 to amino acid 102 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 20 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:1, but excluding the poly(A) tail at the  
25 3' end of SEQ ID NO:1; and
    - (ab) the nucleotide sequence of the cDNA insert of clone PL433\_3 deposited under accession number ATCC 98730;
    - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
    - 30 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- 5 (ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and
- (bb) the nucleotide sequence of the cDNA insert of clone PL433\_3 deposited under accession number ATCC 98730;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 10 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 373 to nucleotide 960, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 373 to nucleotide 960, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 373 to nucleotide 960. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 457 to nucleotide 960, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 457 to nucleotide 960, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 457 to nucleotide 960.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 30 (a) the amino acid sequence of SEQ ID NO:2;
- (b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and

(c) the amino acid sequence encoded by the cDNA insert of clone PL433\_3 deposited under accession number ATCC 98730; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred  
5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from  
10 amino acid 93 to amino acid 102 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- 15 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 325 to nucleotide 528;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 487 to nucleotide 528;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pm198\_3 deposited under accession  
20 number ATCC 98730;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pm198\_3 deposited under accession number ATCC 98730;
- (f) a polynucleotide comprising the nucleotide sequence of a mature  
25 protein coding sequence of clone pm198\_3 deposited under accession number ATCC 98730;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pm198\_3 deposited under accession number ATCC 98730;
- (h) a polynucleotide encoding a protein comprising the amino acid  
30 sequence of SEQ ID NO:4;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

5 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:3.

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 325 to nucleotide 528; the nucleotide sequence of SEQ ID NO:3 from nucleotide 487 to nucleotide 528; the nucleotide sequence of the full-length protein coding sequence of clone pm198\_3 deposited under accession number ATCC 98730; or the nucleotide sequence of a mature protein coding sequence of clone pm198\_3 deposited  
15 under accession number ATCC 98730. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pm198\_3 deposited under accession number ATCC 98730. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological  
20 activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 29 to amino acid 38 of SEQ ID NO:4.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and



- (ab) the nucleotide sequence of the cDNA insert of clone pm198\_3 deposited under accession number ATCC 98730;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that
- 10 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and
- (bb) the nucleotide sequence of the cDNA insert of clone pm198\_3 deposited under accession number ATCC 98730;
- 15 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).
- 20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated
- 25 according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 325 to nucleotide 528, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 325 to nucleotide 528, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 325 to
- 30 nucleotide 528. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 487 to nucleotide 528, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from

nucleotide 487 to nucleotide 528, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 487 to nucleotide 528.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group  
5 consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:4, the  
fragment comprising eight contiguous amino acids of SEQ ID NO:4; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone  
10 pm198\_3 deposited under accession number ATCC 98730;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably  
15 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 29 to amino acid 38 of SEQ ID NO:4.

In one embodiment, the present invention provides a composition comprising an  
20 isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 476 to nucleotide 904;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID  
25 NO:5 from nucleotide 614 to nucleotide 904;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pp128\_1 deposited under accession number ATCC 98730;
- (e) a polynucleotide encoding the full-length protein encoded by the  
30 cDNA insert of clone pp128\_1 deposited under accession number ATCC 98730;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pp128\_1 deposited under accession number ATCC 98730;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pp128\_1 deposited under accession number ATCC 98730;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

10 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:5.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 476 to nucleotide 904; the nucleotide sequence of SEQ ID NO:5 from nucleotide 614 to nucleotide 904; the nucleotide sequence of the full-length protein coding sequence of clone pp128\_1 deposited under accession number ATCC 98730; or the nucleotide sequence of a mature protein coding sequence of clone pp128\_1 deposited under accession number ATCC 98730. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pp128\_1 deposited under accession number ATCC 98730. In further preferred  
20  
25  
30  
embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(ab) the nucleotide sequence of the cDNA insert of clone pp128\_1 deposited under accession number ATCC 98730;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(bb) the nucleotide sequence of the cDNA insert of clone pp128\_1 deposited under accession number ATCC 98730;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 476 to nucleotide 904, and extending

contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 476 to nucleotide 904, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 476 to nucleotide 904. Also preferably the polynucleotide isolated according to the above  
5 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 614 to nucleotide 904, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 614 to nucleotide 904, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 614 to nucleotide 904.

10 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
- (b) a fragment of the amino acid sequence of SEQ ID NO:6, the  
15 fragment comprising eight contiguous amino acids of SEQ ID NO:6; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pp128\_1 deposited under accession number ATCC 98730;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6. In further preferred  
20 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from  
25 amino acid 66 to amino acid 75 of SEQ ID NO:6.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID  
30 NO:7 from nucleotide 11 to nucleotide 1210;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 1100 to nucleotide 1210;

- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pt179\_1 deposited under accession number ATCC 98730;
- (e) a polynucleotide encoding the full-length protein encoded by the  
5 cDNA insert of clone pt179\_1 deposited under accession number ATCC 98730;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pt179\_1 deposited under accession number ATCC 98730;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA  
10 insert of clone pt179\_1 deposited under accession number ATCC 98730;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment  
15 comprising eight contiguous amino acids of SEQ ID NO:8;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any  
20 one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:7.
- 25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 11 to nucleotide 1210; the nucleotide sequence of SEQ ID NO:7 from nucleotide 1100 to nucleotide 1210; the nucleotide sequence of the full-length protein coding sequence of clone pt179\_1 deposited under accession number ATCC 98730; or the nucleotide sequence of a mature protein coding sequence of clone pt179\_1 deposited  
30 under accession number ATCC 98730. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pt179\_1 deposited under accession number ATCC 98730. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological

activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 195  
5 to amino acid 204 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 10 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:7, but excluding the poly(A) tail at the  
15 3' end of SEQ ID NO:7; and
    - (ab) the nucleotide sequence of the cDNA insert of clone pt179\_1 deposited under accession number ATCC 98730;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - 20 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that  
25 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:7, but excluding the poly(A) tail at the  
3' end of SEQ ID NO:7; and
    - (bb) the nucleotide sequence of the cDNA insert of clone  
30 pt179\_1 deposited under accession number ATCC 98730;
  - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 11 to nucleotide 1210, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 11 to nucleotide 1210, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 11 to nucleotide 1210. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 1100 to nucleotide 1210, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 1100 to nucleotide 1210, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 1100 to nucleotide 1210.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone pt179\_1 deposited under accession number ATCC 98730;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 195 to amino acid 204 of SEQ ID NO:8.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:



- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 60 to nucleotide 731;
- 5 (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pt204\_1 deposited under accession number ATCC 98730;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pt204\_1 deposited under accession number ATCC 98730;
- 10 (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pt204\_1 deposited under accession number ATCC 98730;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pt204\_1 deposited under accession number ATCC 98730;
- 15 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;
- 20 (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:9.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 60 to nucleotide 731; the nucleotide sequence of the full-length protein coding sequence of clone pt204\_1 deposited under accession number ATCC 98730; or the nucleotide sequence of a mature protein coding sequence of clone pt204\_1 deposited under accession number ATCC 98730. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert

30

of clone pt204\_1 deposited under accession number ATCC 98730. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a polynucleotide encoding  
5 a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 107 to amino acid 116 of SEQ ID NO:10.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ  
10 ID NO:9.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize  
15 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and
    - (ab) the nucleotide sequence of the cDNA insert of clone  
20 pt204\_1 deposited under accession number ATCC 98730;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - (iii) isolating the DNA polynucleotides detected with the probe(s);
- 25 and
- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - 30 (ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and
    - (bb) the nucleotide sequence of the cDNA insert of clone pt204\_1 deposited under accession number ATCC 98730;

- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9. Also preferably the polynucleotide isolated  
10 according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 60 to nucleotide 731, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 60 to nucleotide 731, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 60 to  
15 nucleotide 731.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- 20 (b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pt204\_1 deposited under accession number ATCC 98730;

the protein being substantially free from other mammalian proteins. Preferably such  
25 protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ  
30 ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 107 to amino acid 116 of SEQ ID NO:10.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 862 to nucleotide 1194;
- 5 (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pu334\_2 deposited under accession number ATCC 98730;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pu334\_2 deposited under accession number ATCC 98730;
- 10 (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pu334\_2 deposited under accession number ATCC 98730;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pu334\_2 deposited under accession number ATCC 98730;
- 15 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;
- 20 (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:11.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 862 to nucleotide 1194; the nucleotide sequence of the full-length protein coding sequence of clone pu334\_2 deposited under accession number ATCC 98730; or the nucleotide sequence of a mature protein coding sequence of clone pu334\_2 deposited under accession number ATCC 98730. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert

30

of clone pu334\_2 deposited under accession number ATCC 98730. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a polynucleotide encoding  
5 a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID NO:12.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ  
10 ID NO:11.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize  
15 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and
    - (ab) the nucleotide sequence of the cDNA insert of clone  
20 pu334\_2 deposited under accession number ATCC 98730;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - (iii) isolating the DNA polynucleotides detected with the probe(s);

25 and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:11, but excluding the poly(A) tail at the  
30 3' end of SEQ ID NO:11; and
    - (bb) the nucleotide sequence of the cDNA insert of clone pu334\_2 deposited under accession number ATCC 98730;

- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide products of step (b)(iii).
- 5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the
- 10 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 862 to nucleotide 1194, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 862 to nucleotide 1194, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide
- 15 862 to nucleotide 1194.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
  - 20 (b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone pu334\_2 deposited under accession number ATCC 98730;
- the protein being substantially free from other mammalian proteins. Preferably such
- 25 protein comprises the amino acid sequence of SEQ ID NO:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ
- 30 ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID NO:12.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 289 to nucleotide 456;
- 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 418 to nucleotide 456;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pv213\_1 deposited under accession number ATCC 98730;
- 10 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pv213\_1 deposited under accession number ATCC 98730;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pv213\_1 deposited under accession number ATCC 98730;
- 15 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pv213\_1 deposited under accession number ATCC 98730;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least
- 30 25% of the length of SEQ ID NO:13.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 289 to nucleotide 456; the nucleotide sequence of SEQ ID NO:13 from nucleotide 418 to nucleotide 456; the nucleotide sequence of the full-length protein coding sequence of clone pv213\_1 deposited under accession number ATCC 98730; or the

nucleotide sequence of a mature protein coding sequence of clone pv213\_1 deposited under accession number ATCC 98730. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pv213\_1 deposited under accession number ATCC 98730. In further preferred  
5 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having  
10 biological activity, the fragment comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID NO:14.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.

Further embodiments of the invention provide isolated polynucleotides produced  
15 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
    - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
      - 20 (aa) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and
      - (ab) the nucleotide sequence of the cDNA insert of clone pv213\_1 deposited under accession number ATCC 98730;
    - (ii) hybridizing said probe(s) to human genomic DNA in  
25 conditions at least as stringent as 4X SSC at 50 degrees C; and
    - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
    - 30 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
      - (ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and



- (bb) the nucleotide sequence of the cDNA insert of clone  
pv213\_1 deposited under accession number ATCC 98730;
- (ii) hybridizing said primer(s) to human genomic DNA in  
conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a  
nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and  
extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ  
10 ID NO:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:13, but  
excluding the poly(A) tail at the 3' end of SEQ ID NO:13. Also preferably the  
polynucleotide isolated according to the above process comprises a nucleotide sequence  
corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 289 to nucleotide  
456, and extending contiguously from a nucleotide sequence corresponding to the 5' end  
15 of said sequence of SEQ ID NO:13 from nucleotide 289 to nucleotide 456, to a nucleotide  
sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide  
289 to nucleotide 456. Also preferably the polynucleotide isolated according to the above  
process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID  
NO:13 from nucleotide 418 to nucleotide 456, and extending contiguously from a  
20 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from  
nucleotide 418 to nucleotide 456, to a nucleotide sequence corresponding to the 3' end of  
said sequence of SEQ ID NO:13 from nucleotide 418 to nucleotide 456.

In other embodiments, the present invention provides a composition comprising  
a protein, wherein said protein comprises an amino acid sequence selected from the group  
25 consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
- (b) a fragment of the amino acid sequence of SEQ ID NO:14, the  
fragment comprising eight contiguous amino acids of SEQ ID NO:14; and
- (c) the amino acid sequence encoded by the cDNA insert of clone  
30 pv213\_1 deposited under accession number ATCC 98730;

the protein being substantially free from other mammalian proteins. Preferably such  
protein comprises the amino acid sequence of SEQ ID NO:14. In further preferred  
embodiments, the present invention provides a protein comprising a fragment of the  
amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID NO:14.

5           In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- (b)     a polynucleotide comprising the nucleotide sequence of SEQ ID  
10     NO:15 from nucleotide 142 to nucleotide 939;
- (c)     a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 286 to nucleotide 939;
- (d)     a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone px129\_1 deposited under accession  
15     number ATCC 98730;
- (e)     a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone px129\_1 deposited under accession number ATCC 98730;
- (f)     a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone px129\_1 deposited under accession number  
20     ATCC 98730;
- (g)     a polynucleotide encoding a mature protein encoded by the cDNA insert of clone px129\_1 deposited under accession number ATCC 98730;
- (h)     a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- (i)     a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;
- (j)     a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k)     a polynucleotide which encodes a species homologue of the protein  
30     of (h) or (i) above ;
- (l)     a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:15.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 142 to nucleotide 939; the nucleotide sequence of SEQ ID NO:15 from nucleotide 286 to nucleotide 939; the nucleotide sequence of the full-length protein coding sequence of clone px129\_1 deposited under accession number ATCC 98730; or the nucleotide sequence of a mature protein coding sequence of clone px129\_1 deposited under accession number ATCC 98730. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone px129\_1 deposited under accession number ATCC 98730. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 128 to amino acid 137 of SEQ ID NO:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and
    - (ab) the nucleotide sequence of the cDNA insert of clone px129\_1 deposited under accession number ATCC 98730;
  - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
  - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and

(bb) the nucleotide sequence of the cDNA insert of clone px129\_1 deposited under accession number ATCC 98730;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 142 to nucleotide 939, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 142 to nucleotide 939, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 142 to nucleotide 939. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 286 to nucleotide 939, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 286 to nucleotide 939, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 286 to nucleotide 939.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:16;

(b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and

(c) the amino acid sequence encoded by the cDNA insert of clone px129\_1 deposited under accession number ATCC 98730;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids  
10 of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 128 to amino acid 137 of SEQ ID NO:16.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial,  
15 yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

20 (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and

(b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention.

25 Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically  
30 effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

5

### DETAILED DESCRIPTION

#### ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

#### Clone "PL433\_3"

A polynucleotide of the present invention has been identified as clone "PL433\_3". PL433\_3 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. PL433\_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "PL433\_3 protein").

The nucleotide sequence of PL433\_3 as presently determined is reported in SEQ ID NO:1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the PL433\_3 protein

corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 16 to 28 of SEQ ID NO:2 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 29. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain  
5 should the predicted leader/signal sequence not be separated from the remainder of the PL433\_3 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone PL433\_3 should be approximately 1300 bp.

The nucleotide sequence disclosed herein for PL433\_3 was searched against the  
10 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. PL433\_3 demonstrated at least some similarity with sequences identified as AA317353 (EST19261 Retina II Homo sapiens cDNA 5' end similar to hypothetical transmembrane protein nma), L39064 (Homo sapiens interleukin 9 receptor (IL9R) gene, complete cds), and U23070 (Human putative transmembrane protein (nma)  
15 mRNA, complete cds). Based upon sequence similarity, pl433\_3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the pl433\_3 protein sequence, near the C-terminus of SEQ ID NO:2.

20 Clone "pm198\_3"

A polynucleotide of the present invention has been identified as clone "pm198\_3". pm198\_3 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis  
25 of computer analysis of the amino acid sequence of the encoded protein. pm198\_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pm198\_3 protein").

The nucleotide sequence of pm198\_3 as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. What applicants presently believe to be the proper  
30 reading frame and the predicted amino acid sequence of the pm198\_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 42 to 54 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 55. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain

should the predicted leader/signal sequence not be separated from the remainder of the pm198\_3 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pm198\_3 should be approximately 2600 bp.

5        The nucleotide sequence disclosed herein for pm198\_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pm198\_3 demonstrated at least some similarity with sequences identified as AA127419 (zn92a09.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone 565624 3') and AA218943 (zr02h04.s1 Stratagene NT2 neuronal precursor  
10 937230 Homo sapiens cDNA clone 650359 3'). Based upon sequence similarity, pm198\_3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the pm198\_3 protein sequence, centered around amino acids 25 and 45 of SEQ ID NO:4, respectively.

15

Clone "pp128\_1"

A polynucleotide of the present invention has been identified as clone "pp128\_1". pp128\_1 was isolated from a human adult blood (lymphoblastic leukemia MOLT-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S.  
20 Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pp128\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pp128\_1 protein").

The nucleotide sequence of pp128\_1 as presently determined is reported in SEQ  
25 ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pp128\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Amino acids 34 to 46 of SEQ ID NO:6 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 47. Due to the hydrophobic nature  
30 of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pp128\_1 protein.

Another potential pp128\_1 reading frame and predicted amino acid sequence is encoded by basepairs 648 to 935 of SEQ ID NO:5 and is reported in SEQ ID NO:25; the



TopPredII computer program predicts a potential transmembrane domain near the C-terminus of the SEQ ID NO:25 amino acid sequence. A frameshift in the nucleotide sequence of SEQ ID NO:5 between about nucleotide 476 to about nucleotide 907 could join together portions of the overlapping reading frames of SEQ ID NO:6 and SEQ ID NO:25.

5       The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pp128\_1 should be approximately 1200 bp.

      The nucleotide sequence disclosed herein for pp128\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pp128\_1 demonstrated at least some similarity with sequences  
10 identified as AA251744 (zs09e04.r1 NCI\_CGAP\_GCB1 Homo sapiens cDNA clone IMAGE:684702 5'), Q77325 (Human genome fragment (Preferred)); T48384 (yb46c01.s1 Homo sapiens cDNA clone 74208 3'), and W63545 (zc56d12.r1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 326327 5'). Based upon sequence similarity, pp128\_1 proteins and each similar protein or peptide may share at least some activity.

15

Clone "pt179\_1"

      A polynucleotide of the present invention has been identified as clone "pt179\_1". pt179\_1 was isolated from a human adult blood (lymphoblastic leukemia MOLT-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S.  
20 Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pt179\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pt179\_1 protein").

      The nucleotide sequence of pt179\_1 as presently determined is reported in SEQ ID  
25 NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pt179\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 351 to 363 of SEQ ID NO:8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 364. Due to the  
30 hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pt179\_1 protein.

      The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pt179\_1 should be approximately 1800 bp.

The nucleotide sequence disclosed herein for pt179\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pt179\_1 demonstrated at least some similarity with sequences identified as AA001677 (zh85e09.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 428104 3'), AA436536 (zv08g07.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 753084 5'), AA452649 (zx33h03.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 788309 5'), and H51991 (yq32f07.r1 Homo sapiens cDNA clone 197509 5'). Based upon sequence similarity, pt179\_1 proteins and each similar protein or peptide may share at least some activity.

10

Clone "pt204\_1"

A polynucleotide of the present invention has been identified as clone "pt204\_1". pt204\_1 was isolated from a human adult blood (lymphoblastic leukemia MOLT-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pt204\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pt204\_1 protein").

The nucleotide sequence of pt204\_1 as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pt204\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pt204\_1 should be approximately 2200 bp.

The nucleotide sequence disclosed herein for pt204\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pt204\_1 demonstrated at least some similarity with sequences identified as AA223139 (zr07g01.r1 Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone 650832 5') and AA223140 (zr07g01.s1 Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone 650832 3'). The predicted amino acid sequence disclosed herein for pt204\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pt204\_1 protein demonstrated at least some similarity to sequences identified as Z70213 (ZK930.2

[*Caenorhabditis elegans*)). Based upon sequence similarity, pt204\_1 proteins and each similar protein or peptide may share at least some activity.

pt204\_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 29 kDa was detected in membrane fractions using SDS  
5 polyacrylamide gel electrophoresis.

#### Clone "pu334\_2"

A polynucleotide of the present invention has been identified as clone "pu334\_2". pu334\_2 was isolated from a human adult blood (promyelocytic leukemia HL-60) cDNA  
10 library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pu334\_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pu334\_2 protein").

15 The nucleotide sequence of pu334\_2 as presently determined is reported in SEQ ID NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pu334\_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Another potential pu234\_2 reading frame and predicted amino acid sequence is encoded  
20 by basepairs 1669-2103 of SEQ ID NO:11 and is reported in SEQ ID NO:26; the TopPredII computer program predicts a potential transmembrane within the SEQ ID NO:26 amino acid sequence.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pu334\_2 should be approximately 2800 bp.

25 The nucleotide sequence disclosed herein for pu334\_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pu334\_2 demonstrated at least some similarity with sequences identified as AA347681 (EST54043 Fetal heart II Homo sapiens cDNA 5' end similar to EST containing Alu repeat), AA420363 (vd01h08.s1 Knowles Solter mouse 2 cell Mus musculus  
30 cDNA clone 791295 5' similar to TR G482919 G482919), AA526607 (ni52g05.s1 NCI\_CGAP\_Ov2 Homo sapiens cDNA clone IMAGE 980504 similar to contains Alu repetitive element), AC002365 (Homo sapiens chromosome X clone U177G4, U152H5, U168D5, 174A6, U172D6, and U186B3 from Xp22, complete sequence), and Z82195 (Human DNA sequence from PAC 274L7 on chromosome X contains ESTs). The

predicted amino acid sequence disclosed herein for pu234\_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pu234\_2 protein (SEQ ID NO:12) demonstrated at least some similarity to sequences identified as AF045571 (nucleic acid binding protein [*Oryza sativa*]) and Z81515 (F26H11.i [*Caenorhabditis elegans*]). Based upon sequence similarity, pu234\_2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the SEQ ID NO:12 protein sequence, one around amino acid 25 and another around amino acid 100. The nucleotide sequence of pu234\_2 indicates that it may contain at least one of the following repetitive elements: Alu, SVA.

#### Clone "pv213\_1"

A polynucleotide of the present invention has been identified as clone "pv213\_1". pv213\_1 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pv213\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pv213\_1 protein").

The nucleotide sequence of pv213\_1 as presently determined is reported in SEQ ID NO:13, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pv213\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14. Amino acids 31 to 43 of SEQ ID NO:14 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 44. Due to the hydrophobic nature of this possible leader/signal sequence, it is likely to act as a transmembrane domain should it not be separated from the remainder of the pv213\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pv213\_1 should be approximately 800 bp.

The nucleotide sequence disclosed herein for pv213\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pv213\_1 demonstrated at least some similarity with sequences identified as AA741334 (ob30f08.s1 NCI\_CGAP\_Kid5 Homo sapiens cDNA clone IMAGE:1325223 similar to SW:LAMP\_HUMAN Q13449 LIMBIC SYSTEM-ASSOCIATED

MEMBRANE PROTEIN PRECURSOR). Based upon sequence similarity, pv213\_1 proteins and each similar protein or peptide may share at least some activity.

Clone "px129\_1"

5 A polynucleotide of the present invention has been identified as clone "px129\_1". px129\_1 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. px129\_1 is a full-length clone,  
10 including the entire coding sequence of a secreted protein (also referred to herein as "px129\_1 protein").

The nucleotide sequence of px129\_1 as presently determined is reported in SEQ ID NO:15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the px129\_1 protein  
15 corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16. Amino acids 36 to 48 of SEQ ID NO:16 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 49. Due to the hydrophobic nature of this possible leader/signal sequence, it is likely to act as a transmembrane domain should it not be separated from the remainder of the px129\_1 protein.

20 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone px129\_1 should be approximately 1600 bp.

The nucleotide sequence disclosed herein for px129\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. px129\_1 demonstrated at least some similarity with sequences  
25 identified as AA387876 (vb58c10.r1 Ko mouse embryo 11 5dpc Mus musculus cDNA clone 761202 5') and AF001551 (Homo sapiens chromosome 16 BAC clone CIT987SK-723D3 complete sequence). Based upon sequence similarity, px129\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the px129\_1 protein  
30 sequence near the C-terminus (centered around amino acid 232) of SEQ ID NO:16. The nucleotide sequence of px129\_1 indicates that it may contain an Alu repetitive element.

Deposit of Clones

Clones PL433\_3, pm198\_3, pp128\_1, pt179\_1, pt204\_1, pu334\_2, pv213\_1, and px129\_1 were deposited on April 10, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit  
5 under the Budapest Treaty and were given the accession number ATCC 98730, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

10 Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector  
15 ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped"  
20 (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

25 Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an  
30 oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

<u>Clone</u>	<u>Probe Sequence</u>
PL433_3	SEQ ID NO:17
pm198_3	SEQ ID NO:18
pp128_1	SEQ ID NO:19
5 pt179_1	SEQ ID NO:20
pt204_1	SEQ ID NO:21
pu334_2	SEQ ID NO:22
pv213_1	SEQ ID NO:23
px129_1	SEQ ID NO:24

10

In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

15

The design of the oligonucleotide probe should preferably follow these parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- 20 (b) It should be designed to have a  $T_m$  of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with  $\gamma$ -<sup>32</sup>P ATP (specific activity 6000 Ci/mmol) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmol.

25

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100  $\mu$ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100  $\mu$ g/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated

30

colonies on solid bacteriological media containing L-broth containing ampicillin at 100 µg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the  
5 colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 µg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at  
10 a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The  
15 filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis,  
20 hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, *Bio/Technology* 10, 773-778 (1992) and in R.S.  
25 McDowell, *et al.*, *J. Amer. Chem. Soc.* 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion  
30 could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence



listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be  
5 determinable from the amino acid sequence of the full-length form.

The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated  
10 expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed  
15 sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

The chromosomal location corresponding to the polynucleotide sequences  
20 disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes *in situ*. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to  
25 particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology  
30 Information having the address <http://www.ncbi.nlm.nih.gov/UniGene/>, in order to identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.

Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The

desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* 15(7): 250-254; Lavarosky *et al.*, 1997, *Biochem. Mol. Med.* 62(1): 11-22; and Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* 58: 1-39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* 14(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour *et al.*, 1988, *Nature* 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of

transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmembrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s).

Proteins and protein fragments of the present invention include proteins with  
5 amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and  
10 identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

15 In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle *ed.*, *Methods in Enzymology* 266: 460-480; Altschul *et al.*, 1990, Basic local alignment search tool, *Journal of Molecular*  
20 *Biology* 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, *Nature Genetics* 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, *Proc. Natl. Acad. Sci. USA* 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be  
25 downloaded from <ftp://blast.wustl.edu/blast/executables>. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial,  
30 nonprofit, or academic purposes. In all search programs in the suite – BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX – the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9

for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be  
5 changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison  
10 matrices such as PAM can be utilized.

Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or  
15 polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide  
20 sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian  
25 species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*, *Cricetulus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*,  
30 *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuáñez, 1988, *Ann. Rev. Genet.* 22: 323-351; O'Brien *et al.*, 1993, *Nature*

*Genetics* 3:103-112; Johansson *et al.*, 1995, *Genomics* 25: 682-690; Lyons *et al.*, 1997, *Nature Genetics* 15: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* 13(10): 393-399; Carver and Stubbs, 1997, *Genome Research* 7:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides  
5 or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by  
10 comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to  
15 those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at  
20 least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) <sup>†</sup>	Hybridization Temperature and Buffer <sup>†</sup>	Wash Temperature and Buffer <sup>†</sup>
5	A	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
	B	<50	T <sub>B</sub> <sup>*</sup> ; 1xSSC	T <sub>B</sub> <sup>*</sup> ; 1xSSC
	C	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
	D	<50	T <sub>D</sub> <sup>*</sup> ; 1xSSC	T <sub>D</sub> <sup>*</sup> ; 1xSSC
	E	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
	F	<50	T <sub>F</sub> <sup>*</sup> ; 1xSSC	T <sub>F</sub> <sup>*</sup> ; 1xSSC
10	G	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
	H	<50	T <sub>H</sub> <sup>*</sup> ; 4xSSC	T <sub>H</sub> <sup>*</sup> ; 4xSSC
	I	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
	J	<50	T <sub>J</sub> <sup>*</sup> ; 4xSSC	T <sub>J</sub> <sup>*</sup> ; 4xSSC
	K	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
	L	<50	T <sub>L</sub> <sup>*</sup> ; 2xSSC	T <sub>L</sub> <sup>*</sup> ; 2xSSC
15	M	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
	N	<50	T <sub>N</sub> <sup>*</sup> ; 6xSSC	T <sub>N</sub> <sup>*</sup> ; 6xSSC
	O	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
	P	<50	T <sub>P</sub> <sup>*</sup> ; 6xSSC	T <sub>P</sub> <sup>*</sup> ; 6xSSC
	Q	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
	R	<50	T <sub>R</sub> <sup>*</sup> ; 4xSSC	T <sub>R</sub> <sup>*</sup> ; 4xSSC

†: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

‡: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH<sub>2</sub>PO<sub>4</sub>, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

\*T<sub>B</sub> - T<sub>R</sub>: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T<sub>m</sub>) of the hybrid, where T<sub>m</sub> is determined according to the following equations. For hybrids less than 18 base pairs in length, T<sub>m</sub>(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T<sub>m</sub>(°C) = 81.5 + 16.6(log<sub>10</sub>[Na<sup>+</sup>]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na<sup>+</sup>] is the concentration of sodium ions in the hybridization buffer ([Na<sup>+</sup>] for 1xSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds.,  
5 John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or  
10 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an  
15 expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably  
20 linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the  
25 protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

30 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial

strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).



Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to  
5 provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which  
10 are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by  
15 virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement,  
20 insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement,  
25 insertion or deletion retains the desired activity of the protein.  
30

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art

given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

### USES AND BIOLOGICAL ACTIVITY

5       The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies  
10   or vectors suitable for introduction of DNA).

#### Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express  
15   recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare  
20   with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for  
25   examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those  
30   described in Gyuris *et al.*, 1993, *Cell* 75: 791-803 and in Rossi *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

#### Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

#### Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may

induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bertagnolli et al., *J. Immunol.* 145:1706-1712, 1990; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Bertagnolli, et al., *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon  $\gamma$ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature* 336:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991;

Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immunol. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

#### Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, *Leishmania* spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease.

Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term

tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

5           The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as  
10 described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

15           Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.  
20 Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from  
25 the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/*lpr/lpr* mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and  
30 murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune

response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I  $\alpha$  chain protein and  $\beta_2$



microglobulin protein or an MHC class II  $\alpha$  chain protein and an MHC class II  $\beta$  chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated  
 5 immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated  
 10 immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without  
 15 limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al.,  
 20 J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al.,  
 25 Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: *In vitro*  
 30 antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek,

D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

- 5 Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995;
- 10 Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

- Assays for lymphocyte survival/apoptosis (which will identify, among others,
- 15 proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993;
- 20 Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

- Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.
- 25

#### Hematopoiesis Regulating Activity

- A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell
- 30 lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid

cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. *Cellular Biology* 15:141-151, 1995; Keller et al., *Molecular and Cellular Biology* 13:473-486, 1993; McClanahan et al., *Blood* 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., *Experimental Hematology* 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and

Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

5

#### Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns,  
10 incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as  
15 well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal  
20 disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue  
25 destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in  
30 circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and

in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation

of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

#### Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin  $\alpha$  family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- $\beta$  group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

#### Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al.

APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

#### Hemostatic and Thrombolytic Activity

5       A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting  
10       formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured by the following methods:

15       Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

#### Receptor/Ligand Activity

20       A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands,  
25       receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant  
30       receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:



Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

#### 10        Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

25

#### Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved

extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this  
5 recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells  
10 become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas  
15 to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed  
20 in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the  
25 inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block  
30 the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

#### Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

#### Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s);

effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic  
5 lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another  
10 material or entity which is cross-reactive with such protein.

#### **ADMINISTRATION AND DOSING**

A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a  
15 pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the  
20 carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other  
25 agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor,  
30 thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical

compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in  
5 combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If  
10 administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical  
15 composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is  
20 administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention.  
25 When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid  
30 form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present

invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should  
5 contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

10 The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician  
15 will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 µg to about 100  
20 mg (preferably about 0.1mg to about 10 mg, more preferably about 0.1 µg to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is  
25 contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain  
30 polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the term "antibody" includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, a humanized antibody, or fragments thereof which bind to the indicated protein.

Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein.

Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of  
5 antibody-producing hybridomas in accordance with known methods (see for example, Goding, 1983, *Monoclonal antibodies: principles and practice*, Academic Press Inc., New York; and Yokoyama, 1992, "Production of Monoclonal Antibodies" in *Current Protocols in Immunology*, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons). Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the  
10 relevant protein or fragments thereof in accordance with known methods. Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection of the desired fragments in accordance with known methods (see for example, Goding, *supra*; and Andrew et al., 1992, "Fragmentation of Immunoglobulins" in *Current Protocols in Immunology*, Unit 2.8, Greene Publishing  
15 Assoc. and John Wiley & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, 5,169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from corresponding murine antibodies in accordance with well known methods (see for example, U.S. Patent Nos. 5,530,101, 5,585,089, and 5,693,762). Additionally, human antibodies may be  
20 produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild *et al.*, 1996, *Nature Biotechnology* 14: 845-851; Mendez *et al.*, 1997, *Nature Genetics* 15: 146-156 (erratum *Nature Genetics* 16: 410); and U.S. Patents 5,877,397 and 5,625,126). Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide  
25 immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987).

Monoclonal antibodies binding to the protein of the invention may be useful  
30 diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where



abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

5 For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably  
10 be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the  
15 methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical  
20 applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium  
25 sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other  
30 ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions  
5 from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of  
10 carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to  
15 provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in  
20 question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- $\alpha$  and TGF- $\beta$ ), and insulin-like growth factor (IGF).

The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to  
25 humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of  
30 a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect

the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such  
5 polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without  
10 limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present  
10 invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
  - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
  - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 373 to nucleotide 960;
  - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 457 to nucleotide 960;
  - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone PL433\_3 deposited under accession number ATCC 98730;
  - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone PL433\_3 deposited under accession number ATCC 98730;
  - (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone PL433\_3 deposited under accession number ATCC 98730;
  - (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone PL433\_3 deposited under accession number ATCC 98730;
  - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
  - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;
  - (j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and
  - (k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:1.
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.

3. A host cell transformed with the polynucleotide of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
  - (a) growing a culture of a host cell transformed with the polynucleotide of claim 2 in a suitable culture medium; and
  - (b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. An isolated polynucleotide encoding the protein of claim 6.
8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone PL433\_3 deposited under accession number ATCC 98730.
9. A protein comprising an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEQ ID NO:2;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone PL433\_3 deposited under accession number ATCC 98730;the protein being substantially free from other mammalian proteins.
10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.
12. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 325 to nucleotide 528;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 487 to nucleotide 528;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pm198\_3 deposited under accession number ATCC 98730;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pm198\_3 deposited under accession number ATCC 98730;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone pm198\_3 deposited under accession number ATCC 98730;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone pm198\_3 deposited under accession number ATCC 98730;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;
- (j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and
- (k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:3.

13. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
- (b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and

(c) the amino acid sequence encoded by the cDNA insert of clone pm198\_3 deposited under accession number ATCC 98730; the protein being substantially free from other mammalian proteins.

14. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 476 to nucleotide 904;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 614 to nucleotide 904;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pp128\_1 deposited under accession number ATCC 98730;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pp128\_1 deposited under accession number ATCC 98730;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone pp128\_1 deposited under accession number ATCC 98730;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone pp128\_1 deposited under accession number ATCC 98730;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;
- (j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and
- (k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:5.

15. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
- (b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pp128\_1 deposited under accession number ATCC 98730;

the protein being substantially free from other mammalian proteins.

16. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 11 to nucleotide 1210;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 1100 to nucleotide 1210;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pt179\_1 deposited under accession number ATCC 98730;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pt179\_1 deposited under accession number ATCC 98730;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone pt179\_1 deposited under accession number ATCC 98730;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone pt179\_1 deposited under accession number ATCC 98730;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;
- (j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and



(k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:7.

17. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
- (b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pt179\_1 deposited under accession number ATCC 98730;

the protein being substantially free from other mammalian proteins.

18. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 60 to nucleotide 731;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pt204\_1 deposited under accession number ATCC 98730;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pt204\_1 deposited under accession number ATCC 98730;
- (e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;
- (g) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(f); and
- (h) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50%

formamide, to any one of the polynucleotides specified in (a)-(f), and that has a length that is at least 25% of the length of SEQ ID NO:9.

19. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pt204\_1 deposited under accession number ATCC 98730;

the protein being substantially free from other mammalian proteins.

20. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 862 to nucleotide 1194;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pu334\_2 deposited under accession number ATCC 98730;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pu334\_2 deposited under accession number ATCC 98730;
- (e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;
- (g) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(f); and
- (h) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(f), and that has a length that is at least 25% of the length of SEQ ID NO:11.

21. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone pu334\_2 deposited under accession number ATCC 98730;
- the protein being substantially free from other mammalian proteins.

22. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 289 to nucleotide 456;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 418 to nucleotide 456;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pv213\_1 deposited under accession number ATCC 98730;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pv213\_1 deposited under accession number ATCC 98730;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone pv213\_1 deposited under accession number ATCC 98730;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone pv213\_1 deposited under accession number ATCC 98730;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;
- (j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and

(k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:13.

23. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
  - (b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone pv213\_1 deposited under accession number ATCC 98730;
- the protein being substantially free from other mammalian proteins.

24. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 142 to nucleotide 939;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 286 to nucleotide 939;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone px129\_1 deposited under accession number ATCC 98730;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone px129\_1 deposited under accession number ATCC 98730;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone px129\_1 deposited under accession number ATCC 98730;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone px129\_1 deposited under accession number ATCC 98730;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;

(j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and

(k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:15.

25. A protein comprising an amino acid sequence selected from the group consisting of:


(a) the amino acid sequence of SEQ ID NO:16;

(b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and

(c) the amino acid sequence encoded by the cDNA insert of clone px129\_1 deposited under accession number ATCC 98730;

the protein being substantially free from other mammalian proteins.

FIGURE 1A




**Plasmid name:** pED6dpc2

**Plasmid size:** 5374 bp

**Comments/References:** pED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4485-4490.

FIGURE 1B



Plasmid name: pNOTs

Plasmid size: 4529 bp

**Comments/References:** pNOTs is a derivative of pMT2 (Kaufman et al, 1989. Mol. Cell. Biol. 9:1741-1750). DHFR was deleted and a new polylinker was inserted between EcoRI and HpaI. M13 origin of replication was inserted in the Clal site. SST cDNAs are cloned between EcoRI and NotI

## SEQUENCE LISTING

<110> Jacobs, Kenneth  
 McCoy, John M.  
 LaVallie, Edward R.  
 Collins-Racie, Lisa A.  
 Treacy, Maurice  
 Agostino, Michael J.  
 Steininger II, Robert J.  
 Genetics Institute, Inc.

<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

<130> GI 6068A

<140>

<141>

<160> 26

<170> PatentIn Ver. 2.0

<210> 1

<211> 1310

<212> DNA

<213> Homo sapiens

<400> 1

```

ggcgcgggcg ggagctgcgg cggataccct tgcgtgctgt ggagacccta ctctcttccc 60
tgagaacggc cgctagccgg gactgaaggc cgggagccca ctcccgacct ggggctagcg 120
tgcgtcccta gagtcgagcg gggcaaggga gccagtggcc gccgacgggg gaccgggaaa 180
cttttctggg ctcttgggcg cgcctgttag ccgcgctcca tgctccggca gcggcccgaa 240
accagcccc gccgctgacg gcgcccgcgc ctccgggcag ggcccatgcc ctgcgcgctc 300
cgggggtcgt aggtgcgcgc cgagccgggg ctccggaagc cggcgggggc gccgcggccg 360
tgcggggcgt caatggatcg cactccagc tacatcttca tctggctgca gctggagctc 420
tgcgccatgg ccgtgctgct caccaaaagt gggcgccggg ggcgcacggg gcccggggtc 480
ccgtcctcgc cgcggggcct tggagccggc tgcagaggct ttgttagcgg caggcgaggc 540
tccctcctgc gccggagccg caggctgcga caagttgctg tgttcttaga agtcgcggcg 600
gtggcctggc gcgtggatgc ggactccgat ctaagggcag gcgctgatca gaggtcctc 660
ctggctctgc ctgcggggag cggcgcgctt gcagcccagc ggggagcggg gccggagtc 720
cggcctcgac gccgccgctt ccgcaccctg ggggctcggg cggccgggag gaatcgaga 780
tcctggcctg tagctgccgc gtgccctcag cgtgtctgtg tgagtgcctc aggggtgtatt 840
tctgtgagtg tgtctctgag tctcagtatc cctaaatgca tttttgtgtc tctgagtg 900
gttgtgwttc tgaaagtgtg tctgaacctc tgtatcactc agcgtatctc tgtgtctctt 960
tgaatgtatc tctgaatgca tttctgtgtc tctttctgag tctttgtgtc tctgaatgtg 1020
tgagtctctg tatctctgat cttgagtggt tctttctgaa tgcatttctg tgtctgtctc 1080
taagtgtctt tgtatctctg aatgtgcac tgagtctctg tgtgagtggt tctctgcgta 1140
catctctctg tgtgcgagcg agtgtgtggg tctccctgag agtttaggtg tccgaggtgt 1200
gcagaagtgt gtgtgtgtgt gcttttcagc agccgggagg agtaggctct gtcagcgtct 1260
cactgccact cacctcatat ttacaaaaca ggaccaaaaa aaaaaaaaaa 1310

```

<210> 2

<211> 196

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Asp Arg His Ser Ser Tyr Ile Phe Ile Trp Leu Gln Leu Glu Leu
  1                   5                   10                   15

```



Cys Ala Met Ala Val Leu Leu Thr Lys Ser Gly Cys Arg Gly Arg Thr  
           20                                  25                                  30  
 Gly Pro Gly Val Pro Ser Ser Pro Arg Gly Phe Gly Ala Gly Cys Arg  
           35                                  40                                  45  
 Gly Phe Val Ser Gly Arg Arg Gly Ser Leu Leu Arg Arg Ser Arg Arg  
           50                                  55                                  60  
 Ser Arg Gln Val Ala Val Phe Leu Glu Val Ala Ala Val Ala Trp Arg  
           65                                  70                                  75                                  80  
 Val Asp Ala Asp Ser Asp Leu Arg Ala Gly Ala Asp Gln Arg Val Leu  
                                   85                                  90                                  95  
 Leu Ala Leu Pro Ala Gly Ser Gly Ala Phe Ala Ala Gln Arg Gly Ala  
           100                                  105                                  110  
 Gly Pro Glu Ser Arg Pro Arg Arg Arg Arg Phe Arg Thr Leu Gly Ala  
           115                                  120                                  125  
 Arg Ala Ala Gly Arg Asn Arg Arg Ser Trp Pro Val Ala Ala Ala Cys  
           130                                  135                                  140  
 Pro Gln Arg Val Cys Val Ser Ala Ser Gly Cys Ile Ser Val Ser Val  
           145                                  150                                  155                                  160  
 Ser Leu Ser Leu Ser Ile Pro Lys Cys Ile Phe Val Ser Leu Ser Val  
                                   165                                  170                                  175  
 Val Val Phe Leu Lys Val Cys Leu Asn Leu Cys Ile Thr Gln Arg Ile  
           180                                  185                                  190  
 Ser Val Ser Leu  
           195

&lt;210&gt; 3

&lt;211&gt; 2608

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

tccttttttg ccatacagta cacatgtaat ctggaaaatc atacctttgt caatttttaa 60  
 cataactttt ggcattttcc agatttatac tatgaacatt ggggtaatac atttttattt 120  
 ttcatgtgta tatgacagct aaggggcaaa tgattcaagt atatttttaa tcagaagtat 180  
 tcaaattatt ttgtataat actgttcagt acttccaaga ataagctctg acaacagcca 240  
 ttgtttctgc ttccactcat attctctaca cattttaata cagaaatttt tgagaggggg 300  
 ttactttatt gcttgtgggt tagtatgtct cttacttcaa ttaagggtac ttatttggtt 360  
 tgccttaage attacttttt taactttgtg ccatttggtc ttacttttt atggatgttt 420  
 tcaaagaaac tattttatat tcaatctagt ttatttagtc tactgtattt ctatttcgtg 480  
 gaagcctttt cccctcaaat aatatattat atcatttttg gacttatata aatgataatt 540  
 aaataaattt ttttcttaat actgttggac ttgtatata caagttcaaa taactttttc 600  
 gaagatagtt tcttatataa atgtaattta atttttttac tcttctatac agttccttag 660  
 atgtaaaaga attagcacia tctctggcag ttttataaaa gctgttgaag ctcttgcctt 720  
 gcactgtctt taggtatcat aggtatcagg ttgtctttgt gttaatgcca cttcaagtca 780  
 ttatttggtt tctgtatatt ttttacctga ggataagaag aatgaatatt aaatttgaat 840  
 attaaatata tgttactttc caagcactgt ataatgactg ttcagtgaat atcagacttc 900  
 cgtgtcatta aaagtcatga gagacagcac agagagggtta taggttgccct tgggtgtactt 960  
 ttgtccagga gtaacaggga cagaatactt tctttctttc cttcaagtac aagaaggctt 1020

```

tctctacat ttgcgtctac actttatttt aaaagctatc cttttctagt agtattttat 1080
catggcaatg gcatgatgac aacaacagtc tttcattaca gactgaaggg aagcatgtcc 1140
ttacttaaaa tagttctgct actttccctc ctattataag gaaatcttac agattctaaa 1200
aataccttaa tttttctttg atttttattt taccaagtca caaatgtctt tttgatgttt 1260
tgagaattgt tctcatagaa tcacaaatac tgacatttca ttagatgatt attttcctag 1320
aatccccaaa gagcagtggc agtccatggc ttgggtgaag ctagaaattt tcctgcccct 1380
ggtgacctgg taagcctcct gctcggaacc gtgtgagtgg gtgaggaaga tgagagatgg 1440
tcagatggaa gagagaaata catgaactgc tctggcctct ctggttctgt tcttggccca 1500
gagtttttga aaagcagcgg agcatgactg acttcacatg ctcagctttc tcagcctttt 1560
gtttattttg ttgtccctag atttccctgt tgtaaaaggg gcaagaaaag taactcatca 1620
tctctaacac accatggcag cttagccagg tagtcttagt ggtggtgttt aggcataaga 1680
tatgtgatc atcagtctca ggccacagtt tccttacta atcgctcagc ttgagtgttc 1740
tgttctcttc ctgcccattt ccttgaacct cctgctctag ccttggcgga gggagagtgc 1800
tatttgcttt tgttctccct ctgtcttagg aaaagccatc tttaatatag ttcttcacca 1860
ctgttggggg tgttttgtga tttttttttt cttccgaaga actcctggtt gttattggat 1920
tttgattttt aatacaaat attgaatttt ataagcttgt acacaatatt taattagtgt 1980
gaaaggaaac aaagaatgca ggaanaataa tttaatatca acctcagttg acaagggtgt 2040
cagattatcc aattcgggat cctccttttg ttaggttttt gagacaacc tagacctaaa 2100
ctgtgtcaca gacttctgaa tgtttaggca gtgctagtaa tttcctcgta atgattctgt 2160
tattacttcc ctattcttta ttctcttttc ttctgaagat taatgaagtt gaaaattgag 2220
gtggataaat acaaaaaggt agtgtgatag tataagtatc taagtgcaga tgaaagtgtg 2280
ttatatacat ccattcaaaa ttatgcaagt tagtaattac tcaggggtta ctaaattact 2340
ttaatatgct gttgaatcta ctctgttcct tggctagaaa aaattataaa caggactttg 2400
tagtttggga agccaaattg ataatatctt atgttctaaa agttgggcta tacataaatt 2460
attaagaaat atggattttt attcccagga tatgggtgtc attttatgat attacgcagg 2520
atgatgtatt gagtaaaatc agttttgtaa atatgtaaat atgtcataaa taaacaatgc 2580
tttgacttat aaaaaaaaaa aaaaaaaaaa 2608

```

&lt;210&gt; 4

&lt;211&gt; 68

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

```

Met Ser Leu Thr Ser Ile Lys Val Thr Tyr Leu Val Cys Leu Lys His
  1             5             10             15

```

```

Tyr Phe Phe Asn Phe Val Pro Phe Gly Leu Tyr Phe Leu Trp Met Phe
      20             25             30

```

```

Ser Lys Lys Leu Phe Tyr Ile Gln Ser Ser Leu Phe Ser Leu Leu Tyr
      35             40             45

```

```

Phe Tyr Phe Val Glu Ala Phe Ser Pro Gln Ile Ile Tyr Tyr Ile Ile
      50             55             60

```

```

Phe Gly Leu Ile
      65

```

&lt;210&gt; 5

&lt;211&gt; 1106

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

```

agagcccaca ttgtctgtag ccatcaaaaa taataataat aaactggaca gtttacaatc 60
gttggtttct ttcaaaaggc ctttttttga aagaagaaaa ggcagtcacc gttttccact 120
tggggttttg gtttgtgcaa cmggcagggg aggagtgggg acgcgtttgt tctagcttga 180
tttccatggc aacagcagcg gcacgcttgg accccagaac ccagcaccct catcctgttg 240

```

```

ccagaggggc cggaccactg acccctttca ggattccacc acagcccaga ccgtcacctg 300
gacccggtgg catgcaactgt tcccaggaca cctcctcct ctcctggacc tcccttccgt 360
cctggcctcc ctgcctctcc agcccctcct ctgccccac cccagtcttc ccagtggaga 420
tctgcccagc tgggtggtgg cctggcgag agtgggagag gctgccaactg acaggatggc 480
tatgacctgg gacatggaaa cagtgcctc cgcgttctgg tcccagatc ctcgcatcag 540
cgatcatcgtg tgcaccggt tggggggctg gagttccggt tttctttgtt tttctcttt 600
attcgctctt tctcaaagat gggatactga tcagaattgc tctgtatatg cttgggactg 660
gatggaaaga ctttggagca gctgtggggg gtggggggac accgacaacc aaacagacgt 720
gctggctcca gtctgtttt tactttcaaa aaccaacaag cccgacagtg gagectgtcc 780
cctcccgga ggggtgctcat ggccccactc acctcatcac cccacggaaa cttttgtgtc 840
ttgccctgga agacaccga attctttgta cattgacatg ccttctcct tctccctcc 900
cctgtagctg gtctttgttt tactccctcc ctttctgac cawgtawac atattatgk 960
agatatcaty ygcctgaaaa aagactttgt gcggattatt gggaacattg tagcygkty 1020
ygtgttttt ctyacctgt agtctggttc tgaattaaga gaggaaaaaa aagtaattat 1080
gatacattgt aaaaaaaaa aaaaaa 1106

```

&lt;210&gt; 6

&lt;211&gt; 143

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

```

Met Ala Met Thr Trp Asp Met Glu Thr Val Thr Ser Ala Phe Trp Ser
  1              5              10             15

Arg Asp Pro Arg Ile Ser Val Ile Val Cys Thr Gly Leu Gly Gly Trp
      20              25             30

Ser Ser Gly Phe Leu Cys Phe Phe Ser Leu Phe Val Leu Ser Gln Arg
      35              40             45

Trp Asp Thr Asp Gln Asn Cys Ser Val Tyr Ala Trp Asp Trp Met Glu
      50              55             60

Arg Leu Trp Ser Ser Cys Gly Gly Trp Gly Asp Thr Asp Asn Gln Thr
      65              70             75             80

Asp Val Leu Ala Pro Val Leu Phe Leu Leu Ser Lys Thr Asn Lys Pro
      85              90             95

Asp Ser Gly Ala Cys Pro Leu Pro Gly Gly Cys Ser Trp Pro His Ser
      100             105             110

Pro His His Pro Thr Glu Thr Phe Val Ser Cys Pro Gly Arg His Pro
      115             120             125

Asn Ser Leu Tyr Ile Asp Met Pro Phe Ser Phe Leu Pro Pro Leu
      130             135             140

```

&lt;210&gt; 7

&lt;211&gt; 1882

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

```

aaaaaaagtg atgaaaaatt ttgaatccag agttgaattc acagaagatt tgcagaaaat 60
gagcgatgct gcaggtgata ttgttgacat acgagaagaa attaaatgtg acttcgaatt 120
taaaagcaaaa caccgaattg ctcataaacc gcattccaaa ccaaaaactt cagatatttt 180
tgaagcagat attgcaaatg atgtgaaatc caaggatttg ctagctgata aagaactgtg 240

```

```

ggctcgactt gaagaactag agagacagga agaattgctg ggtgaacttg atagtaagcc 300
tgatactgtg attgcaaatg gagaagatac gacatcttct gaagaggaaa aggaagatcg 360
taacacaaat gtgaatgcga tgcatacaagt aacagactct catactcctt gtcataagga 420
tggtgcaagt tcagaacatc tcagtgggtca agtgaatagt cagttgaact gttcagttaa 480
tggttccagt tcttaccaca gtgatgatga tgatgatgat gatgacgacg acgacgacaa 540
cattgacgac gatgatgggtg ataacgacca tgaggcttta ggggttggag ataattctat 600
accaacaata tttttttcac atactgttga gcctaagagg gtccgaataa atactggaaa 660
gaataccact ttaaaattca gtgaaaagaa agaagaagcc aaacgtaaac gaaagaacag 720
cactggcagt gccactctg cccaggagct gccgaccatc aggacgcctg cagacattta 780
cagagccttt gttgatgttg tgaatggaga atatgtccct cgcaaatcca tcctgaagtc 840
tcgaagtaga gagaatagtg tgtgtagcga cactagttaa agcagtgtcg ctgaatttga 900
tgataggcgg ggagttttga ggagtatcag ctgcgaagaa gccacttgca gtgacaccag 960
tgagagcatt ttggaagagg aaccacaaga aaatcaaaag aaacttttgc ccttatcagt 1020
aacacctgag gctttttctg gaactgttat agaaaaagaa tttgtatcac cttccttaac 1080
accaccccca gccattgtc atccgcact accactatt ccagaacgaa aggaagttct 1140
gttggaagca tctgaagaaa ctggaaagag ggtttcaaag tttaaagctg ccagattgca 1200
acagaaagac taggccctgt ctaggaaatg ggaatttaca tcctaaaacc tagttgttca 1260
ttgttttaga gtatctatag caaaataggt tacatgtagt ttgaaataag gtatcctgag 1320
ttacttttgc aacaagttct tttaccctta cccgtggtat ttgaaaaaaa tcaaggtaac 1380
tgtctgaata ctttaatatc agcttgtttt gtgaattctc tgaatactgt caacactctt 1440
atctaagttt gcctttatga tgcagtggca gcattttgaa ttacttttca aagaatactg 1500
ttcatatgca ttgtttttgt gtttcaaact aaatacaggc agttttgtgc cagctgtgat 1560
attgtgcata ccatatggac cattttaaag aaaattttta aatttcaaat agattcaaca 1620
attacattac ttgctttcac attttaaagg cactttaaaa aaatctactt ctctttagg 1680
ttttgcggct agttggctat tcaagaaaacc tcgcccctct gaatgtcata ctgtaatctt 1740
taaggaagaa agctacatga attaattgta ctctatggga aaatttcttt ggaaagatat 1800
tttgtaaaac ttttttttcc aagtaaaaac tttatgaaac ttggtctcca aaaaaaaaaa 1860
aaaaaaaaa aaaaaaaaaa aa 1882

```

&lt;210&gt; 8

&lt;211&gt; 400

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

```

Met Lys Asn Phe Glu Ser Arg Val Glu Phe Thr Glu Asp Leu Gln Lys
  1             5             10            15

```

```

Met Ser Asp Ala Ala Gly Asp Ile Val Asp Ile Arg Glu Glu Ile Lys
          20             25            30

```

```

Cys Asp Phe Glu Phe Lys Ala Lys His Arg Ile Ala His Lys Pro His
  35             40            45

```

```

Ser Lys Pro Lys Thr Ser Asp Ile Phe Glu Ala Asp Ile Ala Asn Asp
  50             55            60

```

```

Val Lys Ser Lys Asp Leu Leu Ala Asp Lys Glu Leu Trp Ala Arg Leu
  65             70            75            80

```

```

Glu Glu Leu Glu Arg Gln Glu Glu Leu Leu Gly Glu Leu Asp Ser Lys
          85             90            95

```

```

Pro Asp Thr Val Ile Ala Asn Gly Glu Asp Thr Thr Ser Ser Glu Glu
  100            105            110

```

```

Glu Lys Glu Asp Arg Asn Thr Asn Val Asn Ala Met His Gln Val Thr
  115            120            125

```

```

Asp Ser His Thr Pro Cys His Lys Asp Val Ala Ser Ser Glu Pro Phe

```

130                      135                      140  
 Ser Gly Gln Val Asn Ser Gln Leu Asn Cys Ser Val Asn Gly Ser Ser  
 145                      150                      155                      160  
 Ser Tyr His Ser Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp Asp  
 165                      170                      175  
 Asn Ile Asp Asp Asp Asp Gly Asp Asn Asp His Glu Ala Leu Gly Val  
 180                      185                      190  
 Gly Asp Asn Ser Ile Pro Thr Ile Tyr Phe Ser His Thr Val Glu Pro  
 195                      200                      205  
 Lys Arg Val Arg Ile Asn Thr Gly Lys Asn Thr Thr Leu Lys Phe Ser  
 210                      215                      220  
 Glu Lys Lys Glu Glu Ala Lys Arg Lys Arg Lys Asn Ser Thr Gly Ser  
 225                      230                      235                      240  
 Gly His Ser Ala Gln Glu Leu Pro Thr Ile Arg Thr Pro Ala Asp Ile  
 245                      250                      255  
 Tyr Arg Ala Phe Val Asp Val Val Asn Gly Glu Tyr Val Pro Arg Lys  
 260                      265                      270  
 Ser Ile Leu Lys Ser Arg Ser Arg Glu Asn Ser Val Cys Ser Asp Thr  
 275                      280                      285  
 Ser Glu Ser Ser Ala Ala Glu Phe Asp Asp Arg Arg Gly Val Leu Arg  
 290                      295                      300  
 Ser Ile Ser Cys Glu Glu Ala Thr Cys Ser Asp Thr Ser Glu Ser Ile  
 305                      310                      315                      320  
 Leu Glu Glu Glu Pro Gln Glu Asn Gln Lys Lys Leu Leu Pro Leu Ser  
 325                      330                      335  
 Val Thr Pro Glu Ala Phe Ser Gly Thr Val Ile Glu Lys Glu Phe Val  
 340                      345                      350  
 Ser Pro Ser Leu Thr Pro Pro Pro Ala Ile Ala His Pro Ala Leu Pro  
 355                      360                      365  
 Thr Ile Pro Glu Arg Lys Glu Val Leu Leu Glu Ala Ser Glu Glu Thr  
 370                      375                      380  
 Gly Lys Arg Val Ser Lys Phe Lys Ala Ala Arg Leu Gln Gln Lys Asp  
 385                      390                      395                      400

&lt;210&gt; 9

&lt;211&gt; 2150

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

gtatcccttg gctggtgtat ttgtacatct ctggggacgt gaaattgaca gtgaaaagta 60  
 tggcagatga gcaagaaatc atgtgcaaat tggaaagcat taaagagatc aggaacaaga 120  
 ccctgcagat ggagaagatc aaggctcgtt tgaaggctga gtttgaggca cttgagtcag 180

```

aggaaggca cctgaaggaa tacaagcagg agatggacct tctgctacag gagaagatgg 240
cccatgtgga ggaactccga ctgatccacg ctgacatcaa tgtgatggaa aacactatca 300
aacaatctga gaatgacctt aacaagctgc tagagtctac aaggaggctg catgatgagt 360
ataagccact gaaagaacat gtggatgccc tgcgcatgac tctgggcctg cagaggctcc 420
ctgacttggtg tgaagaagag gagaagcttt ccttggatta ctttgagaag cagaaagcag 480
aatggcagac agaactcag gagccccca tccctgagtc cctggccgct gcagccgctg 540
ccgccaaca gctccaagt gctaggaagc aggatactcg gcagacggcc accttcaggc 600
agcagccccc acctatgaag gcctgcttgt catgtcacca gcaaattcac cggaatgcac 660
ctatatgccc tctttgcaag gccaaagatc ggtcccgga ccccaaaaag ccgaaacgga 720
agcaggatga ataaagaaa ggagagcaca tgaagctttg ctaattataa cccctcacct 780
tgaccagagt cattgatgtc ctgatgtgaa acaacccttg cccaacccca cgaagtctcc 840
tatttaatgt gatggaagca caaccctct ctcactttgc tcctatttct ttctgctctt 900
gggatttctg gtttaggaag agatgtggtt cagggtgctaa acagtgtgtc tgatgatccc 960
ttctctccca ctcacatttc aacccttgcc cttgtttgga gctaaggga gggctaaagg 1020
ctcagatagt attctctatc tcttgctgct gaggcctgga gcctaaggag ctgtagggtc 1080
tgaggggagc gggaggccca tatctgtttt caggtaaagg acccagtatt tcccctcctt 1140
gtacttttgc cttaggttct caagggacaa tagtcttcat gttggattct ccaacaggct 1200
gggtgcatgt atccccctac tcctaccctc atctcatcct taaggcccag aggtagcttg 1260
gacaagccct ccttttcata atcatttggg aggcattggc gtaattcttt agctttcttc 1320
acttctgtct cccacatata ctaaaattct taggtactag gctgtgtgtc ttgggatctt 1380
aagatcaatg aacctttccc caatatctag tctttgcaaa ttctagtaga agatttccac 1440
agtgaatca gtgagccaga ccaactctac atctcctgcc taacctactg cctaagtcac 1500
tagggctgag ggctcggctg taggggcttc cttaggctga gagtgcctcc aggctgacat 1560
ctgtgttggc tttgtttcag aaccattact ctggcacatg ctcaatggta tattgcaggg 1620
aggagaggag tagatttaga tttgagtaaa tgccaatcac tttacacatg aagggtgggtg 1680
ggactttcct tccattcacc ccttgctctc ttggatctga actcttctgg agcctcagct 1740
caggatagct gctggccact cctgtcctgt ggattgtgca ggtggccttt cctcccaaaa 1800
gaaaaggcat caggctcccc aagccccaca gctctccttt ccaccaaaagc cagggttctc 1860
ggtaaggatc ctgaagata agggatgggg atgggggctg actgacaaaa aatttttagc 1920
ccaggtctca gtacctggct ggggaggggg atatttttcc ttccttaagt agttttacat 1980
tgccacagtg tgtatgtgtt cactatataa aatgttctc tgctctttga aagtaagagt 2040
gttgtgtctg taaaaatcct tttaacatgc attcattgga gtaaattctg agtatctact 2100
gtgtattgga taatacaaaa gatgtaatgt catttaaaaa aaaaaaaaaa 2150

```

&lt;210&gt; 10

&lt;211&gt; 224

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

```

Met Ala Asp Glu Gln Ile Met Cys Lys Leu Glu Ser Ile Lys Glu
1           5           10          15

```

```

Ile Arg Asn Lys Thr Leu Gln Met Glu Lys Ile Lys Ala Arg Leu Lys
20          25          30

```

```

Ala Glu Phe Glu Ala Leu Glu Ser Glu Glu Arg His Leu Lys Glu Tyr
35          40          45

```

```

Lys Gln Glu Met Asp Leu Leu Leu Gln Glu Lys Met Ala His Val Glu
50          55          60

```

```

Glu Leu Arg Leu Ile His Ala Asp Ile Asn Val Met Glu Asn Thr Ile
65          70          75          80

```

```

Lys Gln Ser Glu Asn Asp Leu Asn Lys Leu Leu Glu Ser Thr Arg Arg
85          90          95

```

```

Leu His Asp Glu Tyr Lys Pro Leu Lys Glu His Val Asp Ala Leu Arg
100         105         110

```

Met Thr Leu Gly Leu Gln Arg Leu Pro Asp Leu Cys Glu Glu Glu Glu  
115 120 125

Lys Leu Ser Leu Asp Tyr Phe Glu Lys Gln Lys Ala Glu Trp Gln Thr  
130 135 140

Glu Pro Gln Glu Pro Pro Ile Pro Glu Ser Leu Ala Ala Ala Ala Ala  
145 150 155 160

Ala Ala Gln Gln Leu Gln Val Ala Arg Lys Gln Asp Thr Arg Gln Thr  
165 170 175

Ala Thr Phe Arg Gln Gln Pro Pro Pro Met Lys Ala Cys Leu Ser Cys  
180 185 190

His Gln Gln Ile His Arg Asn Ala Pro Ile Cys Pro Leu Cys Lys Ala  
195 200 205

Lys Ser Arg Ser Arg Asn Pro Lys Lys Pro Lys Arg Lys Gln Asp Glu  
210 215 220

<210> 11

<211> 2671

<212> DNA

<213> Homo sapiens

<400> 11

```

aatcgggagc gtttggtaca ttactttttt cttttgtcat tacgtctttt attacagagg 60
ccactgtgca ctccacaatc acacacttac acagctctgc cttgccaagc agtgtagacc 120
ctgccaagca gtgtagacag attctggata actatctttg catccttccc cataccatgt 180
ccccgatgtt gaactgaagc agctccttcc acgttcccta cccgttaatt agccaggcca 240
ctgcccacat tgtcacaac attataattaa ctgaaaaact ggcccatgcc atattccatt 300
atgagaaatt atttttaatt tgattaaatt ccaatgttta ttcagaaaac ctggtagaga 360
ttgaattgct ctatgtacct ttcttagttt tcttcttctt agcataattt gaccatttat 420
cttctacacc tggtgaccc gcatggtcg tgtagtgtaa cttctacttg gtgtttgcgc 480
tttgctttgt tttcaaat tttaattgtg atacattttt aaacctatct aagaaatagc 540
cctgatattg aaatggcttc tgtggaatag gtttgacaga tgtaagtctt tgattctttg 600
gcttttggtt ttgtgcctgt tacagtttta cacacattca ttcagaggaa gacattacca 660
tcagtgtgtg gtttattttt tcaaattcca gtatgttttt aaagacccat atttactaa 720
gcagtgtact gtttgaacc gatgtgagtg actttgtttc cacatgtgat agagcatcag 780
atactggagt ttgccagggg tagaatgggt ggattcagga atgttttagct gactcatagc 840
aggaagtatt cctgtaaaaa aatgaagcaa ggcagggaag acagatttaa gtaccatgca 900
gctcaaacg acaattacat tgtcattttc gttgtgaata cttctaagtt ctatattggc 960
tgtgatcttt gtactaaact gtatcatgga gaatgtgttg gcatcacaga aaaggaggct 1020
aagaaaatgg atgtgtacat ctgtaatgat tgtaaacggg cacaagaggg cagcagttag 1080
gaattgtact gtatctgcag aacacctgca gtcacagtga gttctaata gagcatcaca 1140
tttaataatt taggaagcca aattgctctg actgggtact tatttacttt aaaataaaaa 1200
gcagattttt tctacatttg ttgtacactt acattacaaa ttctttttca ttttttttct 1260
ctttttccct ttttacctac ctttcaaaat ttatcttgct tcatagttaa tgtttgagac 1320
acattgggga aaatgtggtt taatggtaaa tttgattctt caatatgtaa catagaaatt 1380
aatgagatta aaatagcttg acttgtttgg actttatcag tgtttgaaat ggtgctttat 1440
tataggttag aaaaacacta atttgggtat aagctttgag actctgttat taccttatag 1500
gattttgaaac tcccacatgg tacagtacta gttgaaagat ttgtgacttg ttttcagctg 1560
taaaatcaat tgaatgtttc atatttatct ttaaattgggt tctccaaaat tacagtgttc 1620
ttataaattt ttttactgct tgttcgtaac atcaaaaata ctaaattaat gtactggaat 1680
gtcgatcttg aaagtattaa aaccacaata ctaaaactat tttatatccc agggtttagc 1740
aaattttcag gtgcatgctt tattataagt aacatcatcc catctgtttt gaactcacat 1800
ttccatttcg gatcttgcag attttttatt ggccatgatc ggtgtcagaa ttggtaccat 1860

```

```

gggtgctgca ttggcatctt gcagagttag gcagagctca ttgatgagta tgtctgtcca 1920
cagtgccagt caacagagga tgcacatgaca gtgctcacac cactaacaga gaaggatgat 1980
gaggagttga agaggggtgct ccgttcctta cagatgagag ccctctctgtg tgcagcattt 2040
gaaaatgaaa tcagctggca taatttttga agcattttcta ggatttcaag tttccaatgt 2100
taggatttca agtttccaat cttagagtga ttatttactg agtctcagct agtctagtga 2160
agggcttgac aaacttcagt ccttcacata ccagtgtcat gagctttacc atatccccac 2220
accacctcag cttatctaac actcagataa tctaactga ctcacttctt tatacatttt 2280
atttttaaaag aaacttcctc tcactcccat ggattgagaa acagtatgat tagattatag 2340
ttattatttt ccttatgaaa gacagaaaagg tggctgggta cgggggctca cgcctgtaat 2400
cccagcactt tgggggggct gaggtgggca aatcatgagg tcaggagttt gagaccagac 2460
tggccaacat ggtgaaaccc cgtctctact aaaaatacaa aaaactagtc ggggtgtggtg 2520
gcgtgagcct gtaatcccag ctactaggga ggctgaggca ggagaatcgc ttgaacacag 2580
gaagcagagg ttgcagttag ccaagatcga gccatggcac tccagctcgg gtgacagtgt 2640
gagaatctgt ctcaaaaaaa aaaaaaaaaa a 2671

```

&lt;210&gt; 12

&lt;211&gt; 111

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

```

Met Lys Gln Gly Arg Glu Asp Arg Phe Lys Tyr His Ala Ala Gln Asn
  1             5             10             15

```

```

Asp Asn Tyr Ile Val Ile Phe Val Val Asn Thr Ser Lys Phe Tyr Ile
          20             25             30

```

```

Gly Cys Asp Leu Cys Thr Asn Trp Tyr His Gly Glu Cys Val Gly Ile
      35             40             45

```

```

Thr Glu Lys Glu Ala Lys Lys Met Asp Val Tyr Ile Cys Asn Asp Cys
      50             55             60

```

```

Lys Arg Ala Gln Glu Gly Ser Ser Glu Glu Leu Tyr Cys Ile Cys Arg
      65             70             75             80

```

```

Thr Pro Ala Val Thr Val Ser Ser Asn Lys Ser Ile Thr Phe Asn Asn
          85             90             95

```

```

Leu Gly Ser Gln Ile Ala Leu Thr Gly Tyr Leu Phe Thr Leu Lys
      100             105             110

```

&lt;210&gt; 13

&lt;211&gt; 679

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

```

ctcttccaga gggcttgeta tttgcactct ctcttttgaa attgtgttgc ttttactttt 60
cacccttctg cttgggtttt atgagggctt tgtaaagtct tagagagaga gatgggggag 120
accgtttatt tcacaacttt gtgtgtttat acatgaaggg ggaaataaga aagtgaagaa 180
gaaaatacaa catttaaaac aattttacag tccatcatta aaaatttatg tatcattcag 240
gatggagaag gttctactgg gatatgttta tatctactaa gcaaagtgtat gctgtgtaaa 300
gactacacca cactaaggac atctggatgc tgtaaaaata agagaagaac cagatggata 360
ttaagcccc caacacacac tttatccttc cttccttcat cttttttcat ctgtggggaa 420
gaaaataagg tcttgccctt ggtgtttata ttccataac cttttaattc tatttttcat 480
ttgagctgac ttgtagccac ttcagactat caatggaatc ttatgttgag cctttctctg 540
gctttccttc ctccactatc tctccaactt tagagatcat ctcaacttag tattataccc 600
acacccccc aagaacaggg tttgttaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 660

```



aaaaaaaaa aaaaaaaaaa

679

&lt;210&gt; 14

&lt;211&gt; 56

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

Met Leu Cys Lys Asp Tyr Thr Thr Leu Arg Thr Ser Gly Cys Cys Lys  
 1 5 10 15

Asn Lys Arg Arg Thr Arg Trp Ile Leu Ser Pro Pro Thr His Thr Leu  
 20 25 30

Ser Phe Leu Pro Ser Ser Phe Phe Ile Cys Gly Glu Glu Asn Lys Val  
 35 40 45

Leu Pro Leu Val Phe Ile Phe Pro  
 50 55

&lt;210&gt; 15

&lt;211&gt; 1456

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

cggccaaaga ggcctagtta aagcaaattc tagatacatg gtagagacca ggagaaaata 60  
 tgaataactt tcttctaacc aaggagctca gtggataaac catacctcta gattccttgc 120  
 ttccattttt ccagaacaa gatgaggaag agaaagatca gtgtgtgtca acaaacttgg 180  
 gccttattat gcaagaactt tcttaaaaaa tggagaatga aaagagagtc cttaattggaa 240  
 tggctgaatt cattgtcctt actactttgt ttgtatatat atcctcatag tcatcaagta 300  
 aatgattttt cttcactgct taccatggac ctgggacggg tagatacatt taatgaatcc 360  
 agattttctg ttgtatacac acctgtcacc aacacgaccc aacagataat gaataaagta 420  
 gcctctactc ccttctctggc aggtaaagag gtcttgggac tgccagatga ggaaagtatt 480  
 aaagaattca cagcaaatca tcctgaagaa atagtaagag tcacctttac taatacatac 540  
 tcatatcatt tgaagtctct gctaggacat ggaatgccag caaagaagga gcacaaggac 600  
 catacagctc attgttatga aacaaatgaa gatgtttact gtgaagtctc agtattttgg 660  
 aaggaagggt ttgtggctct tcaagctgcc attaatgctg ctattataga aatcacaaca 720  
 aatcactcag tgatggagga gctgatgtca gttactggaa aaaatatgaa gatgcattcc 780  
 ttcatgggtc aatcaggagt tataactgat ttgtaccttt ttctctgcat tatttcattt 840  
 tcctcattca ttactatgc atctgttaat gtcacaagag agaggaaaag gatgaaggcc 900  
 ttgatgacaa tgatgggtct tcgggattca gcgttctggt gagtcaaacg cagcacaaat 960  
 aaataaacgg aggaactcag gaaaactggg aatcttcaat gcatcttttt ttttttgaaa 1020  
 tggagtctcg ctctgtcgcc caggctggag tgcagtggcg tgatctcagc tcaactgcaag 1080  
 ctccgcctca caggttcacg ccattctcct gcctcggcct cccaagtagc tgggactaca 1140  
 ggtgccggcc accatgcctg gataattttt tgtattttct gtagagacgg ggtttcaccg 1200  
 tgtagccag gatggtctcg atctcctgac ctctgtatcc accacctcg gcctcccaa 1260  
 gtgctgggat tacaggcgcg agccaccacg cccggcctct tcaatgcgtc tttattaaaa 1320  
 cctgtttctc cacaaccaag ggggtacaaat gagagatacc tacacagaat aatttcagat 1380  
 catgaacaaa tttccactta gttaatttca gtggggagaa atgctctgca gtgatggaca 1440  
 aaaaaaaaaa aaaaaa 1456

&lt;210&gt; 16

&lt;211&gt; 266

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

Met Arg Lys Arg Lys Ile Ser Val Cys Gln Gln Thr Trp Ala Leu Leu

1	5	10	15
Cys Lys Asn Phe Leu Lys Lys Trp Arg Met Lys Arg Glu Ser Leu Met	20	25	30
Glu Trp Leu Asn Ser Leu Leu Leu Leu Cys Leu Tyr Ile Tyr Pro	35	40	45
His Ser His Gln Val Asn Asp Phe Ser Ser Leu Leu Thr Met Asp Leu	50	55	60
Gly Arg Val Asp Thr Phe Asn Glu Ser Arg Phe Ser Val Val Tyr Thr	65	70	75
Pro Val Thr Asn Thr Thr Gln Gln Ile Met Asn Lys Val Ala Ser Thr	85	90	95
Pro Phe Leu Ala Gly Lys Glu Val Leu Gly Leu Pro Asp Glu Glu Ser	100	105	110
Ile Lys Glu Phe Thr Ala Asn Tyr Pro Glu Glu Ile Val Arg Val Thr	115	120	125
Phe Thr Asn Thr Tyr Ser Tyr His Leu Lys Phe Leu Leu Gly His Gly	130	135	140
Met Pro Ala Lys Lys Glu His Lys Asp His Thr Ala His Cys Tyr Glu	145	150	155
Thr Asn Glu Asp Val Tyr Cys Glu Val Ser Val Phe Trp Lys Glu Gly	165	170	175
Phe Val Ala Leu Gln Ala Ala Ile Asn Ala Ala Ile Ile Glu Ile Thr	180	185	190
Thr Asn His Ser Val Met Glu Glu Leu Met Ser Val Thr Gly Lys Asn	195	200	205
Met Lys Met His Ser Phe Ile Gly Gln Ser Gly Val Ile Thr Asp Leu	210	215	220
Tyr Leu Phe Ser Cys Ile Ile Ser Phe Ser Ser Phe Ile Tyr Tyr Ala	225	230	235
Ser Val Asn Val Thr Arg Glu Arg Lys Arg Met Lys Ala Leu Met Thr	245	250	255
Met Met Gly Leu Arg Asp Ser Ala Phe Trp	260	265	

&lt;210&gt; 17

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;220&gt;

<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 17  
tnaacctcttg tatcactcag cgtatctct 29

<210> 18  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 18  
gnatatgagt ggaagcagaa acaatggct 29

<210> 19  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 19  
tnccatccag tcccaagcat atacagagc 29

<210> 20  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 20  
gntctttatc agctagcaaa tccttggat 29

<210> 21  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 21  
gngagatgta caaatacacc agccaaggg 29

<210> 22  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 22  
cntttctgtg atgccaacac attctccat 29

<210> 23  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 23  
gnttcattg atagtctgaa gtggctaca 29

<210> 24  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 24  
gnattcagcc attccattaa ggactctct 29

<210> 25

&lt;211&gt; 96

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

Met Leu Gly Thr Gly Trp Lys Asp Phe Gly Ala Ala Val Gly Gly Gly  
 1 5 10 15

Gly Thr Pro Thr Thr Lys Gln Thr Cys Trp Leu Gln Ser Cys Phe Tyr  
 20 25 30

Phe Gln Lys Pro Thr Ser Pro Thr Val Glu Pro Val Pro Ser Arg Glu  
 35 40 45

Gly Ala His Gly Pro Thr His Leu Ile Thr Pro Arg Lys Pro Leu Cys  
 50 55 60

Leu Ala Leu Glu Asp Thr Arg Ile Leu Cys Thr Leu Thr Cys Pro Ser  
 65 70 75 80

Pro Ser Ser Leu Pro Cys Ser Trp Ser Leu Phe Tyr Ser Leu Pro Phe  
 85 90 95

&lt;210&gt; 26

&lt;211&gt; 144

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

Met Tyr Trp Asn Val Asp Leu Glu Ser Ile Lys Thr Thr Ile Leu Lys  
 1 5 10 15

Leu Phe Tyr Ile Pro Gly Phe Ser Lys Phe Ser Gly Ala Cys Phe Ile  
 20 25 30

Ile Ser Asn Ile Ile Pro Ser Val Leu Asn Ser His Phe His Phe Gly  
 35 40 45

Ser Cys Arg Phe Phe Ile Gly His Asp Arg Cys Gln Asn Trp Tyr His  
 50 55 60

Gly Cys Cys Ile Gly Ile Leu Gln Ser Glu Ala Glu Leu Ile Asp Glu  
 65 70 75 80

Tyr Val Cys Pro Gln Cys Gln Ser Thr Glu Asp Val Met Thr Val Leu  
 85 90 95

Thr Pro Leu Thr Glu Lys Asp Asp Glu Glu Leu Lys Arg Val Leu Arg  
 100 105 110

Ser Leu Gln Met Arg Ala Pro Leu Cys Ala Ala Phe Glu Asn Glu Ile  
 115 120 125

Ser Trp His Asn Phe Gly Ser Ile Ser Arg Ile Ser Ser Phe Gln Cys  
 130 135 140

## INTERNATIONAL SEARCH REPORT

 International application No.  
 PCT/US99/07885

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 15/00, 15/12; C07K 14/00, 14/435, 7/00

US CL : 435/69.1, 320.1, 325; 536/23.5, 23.1; 530/350, 300

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 320.1, 325; 536/23.5, 23.1; 530/350, 300

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Genbank, Genbank-EST, Geneseq, Swissprot, pir60

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DEGEN et al. Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts. Int. J. Cancer. 1996, Vol. 65, No. 4, pages 460-465, especially Figure 2 and 8, and Genbank Accession Number U23070.	1-3, 7, 9 --- 4-6, 11
X	Database on Genbank, Accession No. AA317353, ADAMS et al. ST19261 Retina II Homo sapiens cDNA 5' end similar to hypothetical transmembrane protein nma, mRNA Sequence. 19 April 1997.	1-3



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

15 JUNE 1999

Date of mailing of the international search report

22 JUL 1999

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ELIANE LAZAR-WESLEY

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/07885

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/07885

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-11, drawn to an isolated polynucleotide having SEQ ID No:1, a nucleotide sequence encoding the protein encoded by the cDNA insert of clone PL433\_3, a protein having SEQ ID No:2, a process for producing the protein and a composition.

Group II, claims 12-13, drawn to an isolated polynucleotide sequence having SEQ ID No:3 and a protein having SEQ ID No:4 encoded by the cDNA insert of clone pm198\_3.

Group III, claims 14-15, drawn to an isolated polynucleotide sequence having SEQ ID No:5 and a protein having SEQ ID No:6 encoded by the cDNA insert of clone pp128\_1.

Group IV, claims 16-17, drawn to an isolated polynucleotide sequence having SEQ ID No:7 and a protein having SEQ ID No:8 encoded by the cDNA insert of clone pt179\_1.

Group V, claims 18-19, drawn to an isolated polynucleotide sequence having SEQ ID No:9 and a protein having SEQ ID No:10 encoded by the cDNA insert of clone pt204\_1.

Group VI, claims 20-21, drawn to an isolated polynucleotide sequence having SEQ ID No:11 and a protein having SEQ ID No:12 encoded by the cDNA insert of clone pu334\_2.

Group VII, claims 22-23, drawn to an isolated polynucleotide sequence having SEQ ID No:13 and a protein having SEQ ID No:14 encoded by the cDNA insert of clone pv213\_1.

Group VIII, claims 24-25, drawn to an isolated polynucleotide sequence having SEQ ID No:15 and a protein having SEQ ID No:16 encoded by the cDNA insert of clone px129\_1.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of Group I is the nucleotide sequence of SEQ ID No:1, the protein of SEQ ID No:2 and a method of making a protein. Groups II-VIII do not share the special technical feature of Group I, because the claims are to different nucleotide sequences and different proteins having different structures and functions.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**